The National Polytechnic Institute (IPN) has issued a warning about the illegal sale of the medication Transferón, patented by the institution. The population is urged to take care of their well-being and purchase the product exclusively at the IPN, following medical consultation, to avoid health risks.
Transferón is not marketed on digital platforms or through self-proclaimed 'authorized' distributors. To combat this situation, the IPN constantly engages in activities to disable email addresses that offer the drug illegally, aiming to prevent counterfeiting and protect its brand.
Legal actions have enabled the identification and elimination of 183 postings on websites, social media, and television, of which 127 have been removed through judicial and administrative measures. The only legitimate way to obtain Transferón is through the External Services and Clinical Research Unit (USEIC) of the National School of Biological Sciences (ENCB) or at the Scientific and Technological Studies Center (CECyT) No. 6 'Miguel Othón de Mendizábal'.
The IPN reaffirms its commitment to combat any attempt to commercialize imitations and counterfeits of its products on e-commerce platforms, social media, and websites. Legal actions have been taken, including filing lawsuits, against individuals and entities promoting the illegal sale of Transferón.
The product is manufactured under a unique, standardized, and controlled process that guarantees its quality. Through websites and social media, counterfeit versions of the medication have been detected, representing a risk to consumer health. In this regard, the IPN has eliminated over 660 infringing profiles on digital platforms and removed 1383 listings of counterfeit products from e-commerce sites.
